Skip to content

US · ZYBT · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Zhengye Biotechnology Holding Limited (ZYBT) intrinsic value and stock valuation

$1.48as of 2026-11-21 · Mkt cap 111.84M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Zhengye Biotechnology Holding Limited DCF and intrinsic value

InvestorsCraft values ZYBT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ZYBT’s statements →

Zhengye Biotechnology Holding Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Jilin, JI 132101 jlzybio.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$116.4M
20212025
Net income
-$-69.78M
20212025
Free cash flow
$700K
20212025
Total equity
$306.7M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$116.4M$186.4M$211.7M$260.3M$214.1M
Operating income-$-68.25M$16.4M$45M$65.8M$52.4M
Net income-$-69.78M$11.3M$31.5M$46.7M$39M
EPSd-$-1.47M$239.8K$666.9K$990.7K$825.9K
Operating cash flow$13.3M$41.1M$48.2M$17.3M$31.8M
Capital expenditure-$-12.63M-$-27.77M-$-11.6M-$-27.33M-$-26.4M
Free cash flow$700K$13.3M$36.6M-$-9.99M$5.41M
Total assets$436.5M$493.3M$499.9M$519.7M$445.3M
Total debt$75.1M$86.4M$89.9M$64.9M$30M
Net debt$24.8M$67.8M$74.8M$55.1M$23.7M
Total equity$306.7M$352.5M$339.3M$356.9M$318.8M
Cash and short-term investments$51.9M$20M$16.3M$9.75M$6.28M
Income statement
20252024202320222021
Revenue$116.4M$186.4M$211.7M$260.3M$214.1M
Cost of revenue$92.5M$95.1M$81.8M$106.8M$88.7M
Gross profit$23.9M$91.3M$129.9M$153.5M$125.4M
Research and development expenses$18M$12.8M$11.9M$13.4M$11.4M
Selling, general and administrative expenses$74.9M$63.8M$66.6M$63.6M$58.2M
Other expenses-$-810K-$-1.78M$6.33M$10.7M$3.45M
Operating expenses$92.1M$74.9M$84.9M$87.7M$73M
Cost and expenses$184.6M$169.9M$166.7M$194.4M$161.7M
Interest income$100K$230K$310K$110K$110K
Interest expense$3.4M$4.04M$4.42M$2.84M$1.05M
Depreciation and amortization$26M$24.2M$23.9M$18.8M$16M
Ebitda-$-42.52M$42.6M$72.1M$85.6M$70.1M
Operating income-$-68.25M$16.4M$45M$65.8M$52.4M
Total other income/expenses, net-$-3.62M-$-2.04M-$-1.22M-$-1.92M$680K
Income before tax-$-71.87M$14.4M$43.8M$63.9M$53.1M
Income tax expense$11.1M$920K$6.25M$8.17M$6.6M
Net income-$-69.78M$11.3M$31.5M$46.7M$39M
Weighted average shares outstanding$47.4M$47.2M$45.7M$45.7M$45.7M
Weighted average diluted shares outstanding$47.4M$47.2M$47.2M$47.2M$47.2M
Balance sheet
20252024202320222021
Cash and short-term investments$51.9M$20M$16.3M$9.75M$6.28M
Net receivables$18.5M$88.5M$99.4M$134.3M$102.2M
Inventory$39.2M$58.2M$58.3M$55.4M$43.6M
Total current assets$137.4M$177.6M$205.6M$214.3M$164.9M
Property, plant and equipment, net$237.3M$255.2M$271.5M$283.7M$255.1M
Goodwill and intangible assets$54.8M$22.8M$16.3M$19.5M$12.1M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$299.1M$315.7M$294.3M$305.4M$280.3M
Total assets$436.5M$493.3M$499.9M$519.7M$445.3M
Accounts payable$44M$43M$45.7M$79.3M$77.6M
Short-term debt$65.9M$81.6M$79.9M$54.9M$30M
Deferred revenue$4.83M$3.69M$3.98M$4.7M$4.28M
Total current liabilities$120.5M$135.9M$150.2M$152.2M$125.6M
Long-term debt$9.18M$4.8M$9.99M$9.99M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.28M$4.8M$10.4M$10.6M$820K
Capital lease obligations$430K$0.00$0.00$0.00$0.00
Total liabilities$129.8M$140.7M$160.6M$162.8M$126.4M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-21.63M$48.2M$38.4M$65.8M$42.3M
Accumulated other comprehensive income (loss)$30.7M$32.7M$31.3M$27.6M$22M
Total equity$306.7M$352.5M$339.3M$356.9M$318.8M
Total investments$1.56M$1.43M$1.22M$0.00$0.00
Total debt$75.1M$86.4M$89.9M$64.9M$30M
Net debt$24.8M$67.8M$74.8M$55.1M$23.7M
Cash flow statement
20252024202320222021
Net income-$-82.97M$13.5M$37.5M$55.7M$46.5M
Depreciation and amortization$26M$24.2M$23.9M$18.8M$16M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$44.8M-$-980K-$-20.49M-$-66.82M-$-33.71M
Accounts receivable$61.4M$11.3M$38.1M-$-47.38M-$-40.91M
Inventory$6.25M-$-5.88M-$-12.9M-$-12.32M-$-12.34M
Accounts payable-$-3.36M-$-400K-$-35.61M-$-9.67M$17.6M
Net cash provided by operating activities$13.3M$41.1M$48.2M$17.3M$31.8M
Investments in property, plant and equipment-$-1.01M-$-13.59M-$-7.4M-$-27.33M-$-19.06M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-12.63M-$-27.66M-$-11.77M-$-27.33M-$-26.27M
Common stock issued$43.1M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-16.02M-$-39.45M-$-21.43M-$-11.05M
Net cash used for financing activities$32.3M-$-22.13M-$-18.98M$13.5M-$-3.05M
Net change in cash$31.7M-$-8.58M$17.4M$3.46M$2.49M
Cash at end of period$50.3M$18.6M$27.2M$9.75M$6.28M
Operating cash flow$13.3M$41.1M$48.2M$17.3M$31.8M
Capital expenditure-$-12.63M-$-27.77M-$-11.6M-$-27.33M-$-26.4M
Free cash flow$700K$13.3M$36.6M-$-9.99M$5.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Zhengye Biotechnology Holding Limited

        Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

        CEO
        Songlin Song
        Employees
        269
        Beta
        -2.69

        Explore

        Frequently asked questions

        What is the intrinsic value of Zhengye Biotechnology Holding Limited (ZYBT)?

        Zhengye Biotechnology Holding Limited (ZYBT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ZYBT undervalued?

        ZYBT trades at a price of $1.48 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.